Novo Nordisk stock news
On August 7, 2026, Novo Nordisk (NVO) shares faced continued downward pressure as analysts digested the implications of the Phase III ZEUS trial failure for ziltivekimab, which overshadowed a second--quarter earnings beat. Despite raising its full--year 2026 adjusted sales and operating profit guidance to a range of 0% to --6% at constant exchange rates, the company reported a 19% decline in reported operating profit due to DKK 6.3 billion in impairment charges, including a DKK 4.0 billion write--down for the discontinued obesity drug monlunabant. Market sentiment remains cautious as the company enters a transition period, balancing strong Wegovy pill uptake against intensifying competition from Eli Lilly and the loss of a key cardiovascular pipeline catalyst.